G Edgren1,2, H Hjalgrim3,4, K Rostgaard3, V Dahl5, K Titlestad6, C Erikstrup7, A Wikman8,9, R Norda10, A Majeed1,11,12. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 2. Department of Cardiology, Södersjukhuset, Stockholm, Sweden. 3. Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. 4. Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark. 5. Department of Monitoring and Evaluation, Public Health Agency of Sweden, Stockholm, Sweden. 6. Department of Clinical Immunology, Odense University Hospital, Odense, Denmark. 7. Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark. 8. Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. 9. Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 10. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. 11. Department of Gastroenterology, The Alfred Health, Melbourne, Vic., Australia. 12. Central Clinical School, Monash University, Melbourne, Vic., Australia.
Abstract
BACKGROUND: Both hepatitis B and C viruses were transmitted through blood transfusion before implementation of donor screening. The existence of additional, yet unknown transfusion transmittable agents causing liver disease could have important public health implications. METHODS: Analyses were based on the Scandinavian Donations and Transfusions (SCANDAT2) database. Cox regression models were used to estimate the hazard ratio (HR) of developing chronic liver disease in recipients of blood from donors who later developed any chronic liver disease compared to recipients who received blood transfusion from healthy donors. We also studied whether the risk of liver disease was increased in patients who received units from 'high-risk' donors, defined as donors who had a higher than expected occurrence of liver disease amongst their previous recipients. All analyses were stratified before and after 1992 to account for the effect of screening for hepatitis C virus. RESULTS: A total of 1 482 922 transfused patients were included in the analyses. Analyses showed evidence of transfusion transmission of liver diseases before, but not after the implementation of hepatitis C virus screening in 1992, with HRs for any liver disease of 1.38 [95% confidence interval (CI), 1.30-1.46] and 0.99 (95% CI, 0.91-1.07), before and after 1992, respectively. Similarly, blood components from 'high-risk' donors conferred increased risks before, but not after 1992. CONCLUSIONS: Our data provide no evidence for transfusion transmission of agents causing liver disease after the implementation of screening for hepatitis B and C, and suggest that if such transmission does occur, it is rare.
BACKGROUND: Both hepatitis B and C viruses were transmitted through blood transfusion before implementation of donor screening. The existence of additional, yet unknown transfusion transmittable agents causing liver disease could have important public health implications. METHODS: Analyses were based on the Scandinavian Donations and Transfusions (SCANDAT2) database. Cox regression models were used to estimate the hazard ratio (HR) of developing chronic liver disease in recipients of blood from donors who later developed any chronic liver disease compared to recipients who received blood transfusion from healthy donors. We also studied whether the risk of liver disease was increased in patients who received units from 'high-risk' donors, defined as donors who had a higher than expected occurrence of liver disease amongst their previous recipients. All analyses were stratified before and after 1992 to account for the effect of screening for hepatitis C virus. RESULTS: A total of 1 482 922 transfused patients were included in the analyses. Analyses showed evidence of transfusion transmission of liver diseases before, but not after the implementation of hepatitis C virus screening in 1992, with HRs for any liver disease of 1.38 [95% confidence interval (CI), 1.30-1.46] and 0.99 (95% CI, 0.91-1.07), before and after 1992, respectively. Similarly, blood components from 'high-risk' donors conferred increased risks before, but not after 1992. CONCLUSIONS: Our data provide no evidence for transfusion transmission of agents causing liver disease after the implementation of screening for hepatitis B and C, and suggest that if such transmission does occur, it is rare.
Authors: Gustaf Edgren; Klaus Rostgaard; Senthil K Vasan; Agneta Wikman; Rut Norda; Ole Birger Pedersen; Christian Erikstrup; Kaspar René Nielsen; Kjell Titlestad; Henrik Ullum; Mads Melbye; Olof Nyrén; Henrik Hjalgrim Journal: Transfusion Date: 2015-01-09 Impact factor: 3.157
Authors: Gustaf Edgren; Henrik Hjalgrim; Klaus Rostgaard; Paul Lambert; Agneta Wikman; Rut Norda; Kjell-Einar Titlestad; Christian Erikstrup; Henrik Ullum; Mads Melbye; Michael P Busch; Olof Nyrén Journal: Ann Intern Med Date: 2016-06-28 Impact factor: 25.391
Authors: Patricia E Hewitt; Samreen Ijaz; Su R Brailsford; Rachel Brett; Steven Dicks; Becky Haywood; Iain T R Kennedy; Alan Kitchen; Poorvi Patel; John Poh; Katherine Russell; Kate I Tettmar; Joanne Tossell; Ines Ushiro-Lumb; Richard S Tedder Journal: Lancet Date: 2014-07-28 Impact factor: 79.321
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Morten Schmidt; Sigrun Alba Johannesdottir Schmidt; Jakob Lynge Sandegaard; Vera Ehrenstein; Lars Pedersen; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2015-11-17 Impact factor: 4.790